RNA Mutation Expression Quantification via Read Pair Classification

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for quantifying RNA expression levels, particularly for neoantigens derived from somatic mutations in tumors, often miss insertions and deletions, leading to misquantification and failure to accurately identify relevant neoantigens for cancer therapies.

Innovation Solution

A system and method for quantifying RNA mutation expression by classifying read pairs as consistent with or inconsistent with specific alleles and isoforms, using contiguously aligned regions and splice junction configurations, to accurately identify neoantigens and their isoforms, thereby enabling the development of targeted cancer therapies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If current methods for quantifying RNA expression levels are used, then the quantification process is simple, but insertions and deletions are missed leading to misquantification

Engineering Contradiction:
ImproveRNA expression quantification accuracyVSAvoidquantification method complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The patent segments the RNA quantification process into distinct stages: read pair classification based on contiguously aligned regions, splice junction configuration analysis, and mutation consistency evaluation. This segmentation allows each aspect to be handled separately with specialized algorithms, improving detection accuracy for insertions and deletions while maintaining manageable system complexity through modular processing steps

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent introduces an intermediary classification system that evaluates read pairs against reference genomes and mutation databases before final quantification. This intermediary step acts as a mediator that filters and validates data, ensuring that insertions and deletions are properly identified and counted, thereby improving measurement precision without directly increasing the core quantification complexity

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If read pairs are classified based on contiguously aligned regions and splice junction configurations, then neoantigens are accurately identified, but processing time increases

Engineering Contradiction:
Improveneoantigen identification accuracyVSAvoidprocessing time
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent performs preliminary classification of read pairs by evaluating contiguously aligned regions and splice junction configurations before full neoantigen analysis. This preliminary action pre-sorts and pre-validates data, so that when neoantigens are identified, the foundation is already established, reducing the time required for subsequent detailed processing while maintaining high identification accuracy

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent applies partial action by focusing classification efforts on specific regions (contiguously aligned regions and splice junctions) that are most critical for neoantigen identification rather than analyzing entire transcripts uniformly. This selective approach concentrates computational resources on high-value areas, improving reliability where it matters most while limiting time consumption through targeted rather than exhaustive analysis

Inventive Principle:
Principle #16Partial or excessive action

3Loss of information

If isoform-specific mutation expression is quantified, then relevant neoantigens are prioritized, but computational requirements increase

Engineering Contradiction:
Improveneoantigen relevance informationVSAvoidcomputational system complexity
Core Design Contradiction:
Loss of informationVSDevice complexity

Solution Approach 1:

The patent applies local quality by quantifying mutation expression specifically at the isoform level rather than treating all transcripts uniformly. This allows the system to identify which specific isoforms express relevant neoantigens, preserving critical relevance information. The computational complexity is managed by applying this detailed analysis only where needed (at isoform-specific locations) rather than across the entire transcriptome

Inventive Principle:
Principle #3Local quality

Data Source

PatentUS20240136013A1Quantification of RNA mutation expression
Publication Date: 2024.04.25 GENENTECH INC
  • US20240136013A1 patent drawing
  • US20240136013A1 patent drawing
  • US20240136013A1 patent drawing

AI summary

A method for quantifying ribonucleic acid (RNA) mutation expression. For each read pair of a read pair group, a set of contiguously aligned regions and a splice junction configuration are identified. Each read pair is within a selected range of a location of interest. Each read pair of the read pair group is classified based on the set of contiguously aligned regions and the splice junction configuration that correspond to each read pair, a reference genome, and a selected mutation. A mutation-centric output is generated for the read pair group.